Key Takeaways

GLP-1 agonists work through multiple mechanisms: insulin secretion, glucagon suppression, delayed gastric emptying, and satiety signaling
Clinical trials show 15-24% weight loss and up to 2.24% HbA1c reduction depending on the medication
Tirzepatide (dual agonist) and retatrutide (triple agonist) represent newer, potentially more effective options
Most side effects are gastrointestinal and transient, improving with gradual dose titration
Steady-state levels are achieved after 4-5 half-lives (3-5 weeks depending on the drug)

Am I a candidate for GLP-1 therapy?

Before anything else: do you qualify? GLP-1 receptor agonists approved for weight loss (semaglutide as Wegovy, tirzepatide as Zepbound) have specific eligibility criteria set by the FDA. Understanding them upfront saves time and sets realistic expectations.

Eligibility criteria

BMI of 30 or higher (obesity, no weight-related conditions required)
BMI of 27 or higher with at least one weight-related condition: type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, or cardiovascular disease
18 years or older (pediatric indications exist for tirzepatide in limited cases)
Willing to combine with lifestyle modification (diet and exercise)

Who should not start GLP-1 therapy

Absolute and relative contraindications:

Personal or family history of medullary thyroid carcinoma (MTC); GLP-1 agonists carry an FDA boxed warning for MTC risk
Multiple Endocrine Neoplasia syndrome type 2 (MEN2); contraindicated due to the same thyroid cancer risk
History of pancreatitis; increased risk of recurrence; discuss carefully with your doctor
Severe gastroparesis; GLP-1 agents slow gastric emptying further, which can significantly worsen this condition
Pregnancy or planned pregnancy; discontinue at least 2 months before trying to conceive
Diabetic retinopathy; rapid glucose lowering can temporarily worsen retinopathy; ophthalmology review is recommended
Severe kidney disease (eGFR below 15); use with caution; dehydration from GI side effects can impair kidney function further

These are broad guidelines. Your prescribing clinician will review your full medical history before deciding whether treatment is appropriate for you.

Before your first injection

Getting a prescription

You need a prescription from a licensed clinician. Two routes are common:

In-person visit: Your primary care physician or an endocrinologist/obesity medicine specialist. Typically involves a physical exam, labs, and an insurance discussion at the same appointment.
Telehealth: Platforms like Ro, Hims & Hers, or LifeMD offer consultations within days. Many work directly with compounding pharmacies, which can significantly reduce cost (see the cost section below).

Baseline labs to get before starting

Ask your prescriber to order these at your first appointment:

HbA1c and fasting glucose (glycemic baseline)
Lipid panel (cholesterol, triglycerides)
Comprehensive metabolic panel (kidney and liver function)
TSH (thyroid function)
Complete blood count
Urine albumin-to-creatinine ratio (if at risk for kidney disease)

Follow-up labs at weeks 4, 8, and 12 let your clinician confirm the medication is working and catch any early issues.

Injection technique

Subcutaneous injection sounds intimidating, but most patients find the pen devices straightforward after the first go. A few things to know:

Injection sites: Abdomen (at least 2 inches from the navel), front of the thigh, or upper outer arm. Rotate sites each week to avoid tissue buildup at any one spot.
Pen storage: Keep unused pens refrigerated (36-46°F / 2-8°C). Once in use, semaglutide pens can be stored at room temperature (below 77°F / 25°C) for up to 4 weeks; tirzepatide pens until the dose is completed.
Travel: A small insulated pouch with an ice pack works for short trips. Extended travel may need a travel fridge.
Compounded vials: If using a compounded version, your pharmacist will provide a reconstitution guide and insulin syringes. See our reconstitution guides for step-by-step instructions.
Hygiene: Wipe the injection site with an alcohol swab, let it dry, then inject at a 90-degree angle. Apply gentle pressure after removing the needle.

Understanding GLP-1 Receptor Agonists

GLP-1 receptor agonists mimic the action of glucagon-like peptide-1, a naturally occurring incretin hormone involved in glucose regulation and energy balance. Native GLP-1 has a half-life of only 1-2 minutes because DPP-4 breaks it down almost immediately. These synthetic analogs are modified to last much longer, days instead of minutes.

How GLP-1 therapies have changed

The drug class started with simple GLP-1 mimetics and has moved toward multi-receptor agonists:

First Generation: Short-acting agents like exenatide (twice daily)
Second Generation: Once-weekly GLP-1 agonists (semaglutide)
Third Generation: Dual agonists targeting GLP-1 and GIP (tirzepatide)
Next Generation: Triple agonists adding glucagon receptor activation (retatrutide)

How each medication works

Semaglutide (Ozempic®/Wegovy®)

Semaglutide is a pure GLP-1 receptor agonist with 94% structural homology to native GLP-1. Its molecular mechanisms include:

Pancreatic effects: Glucose-dependent insulin secretion from β-cells via cAMP/PKA pathway activation
Glucagon suppression: Inhibits inappropriate glucagon release from α-cells
Gastric effects: Delays gastric emptying through vagal and myenteric pathways
Central effects: Activates hypothalamic and brainstem GLP-1 receptors to promote satiety
Cardiovascular benefits: Direct effects on endothelium and myocardium

Note: For those seeking cost-effective alternatives, compounded semaglutide options are widely available through specialized pharmacies, though quality and sourcing considerations apply.

Tirzepatide (Mounjaro®/Zepbound®)

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Activating both receptors produces additive effects:

Enhanced insulin response: GIP and GLP-1 together produce greater insulin secretion than either alone
Improved insulin sensitivity: GIP activation enhances peripheral glucose uptake
Adipose tissue effects: GIP receptors in fat tissue may improve lipid metabolism
Greater weight loss: The dual mechanism produces stronger appetite reduction than GLP-1 alone

Note: For those seeking cost-effective alternatives, compounded tirzepatide options are available through specialized pharmacies, though quality and sourcing considerations apply.

Retatrutide (Investigational)

Currently in Phase 3 trials, retatrutide adds glucagon receptor activation to the dual GIP/GLP-1 mechanism:

Increased energy expenditure: Glucagon activation enhances thermogenesis
Enhanced lipolysis: Promotes fat breakdown and utilization
Hepatic glucose production: Carefully balanced to avoid hyperglycemia
Greater weight loss than dual agonists: Phase 2 data shows up to 24.2% reduction at 48 weeks

Clinical trial data

Weight loss outcomes

Medication	Trial	Duration	Weight Loss	≥10% Loss
Semaglutide 2.4mg	STEP 1	68 weeks	14.9%	69.1%
Semaglutide 7.2mg	STEP UP	72 weeks	20.7%	Not reported
Tirzepatide 15mg	SURMOUNT-1	72 weeks	20.9%	84.3%
Retatrutide 12mg	Phase 2	48 weeks	24.2%	91%

Glycemic control (HbA1c reduction)

Semaglutide: 1.5-2.0% reduction (SUSTAIN trials)
Tirzepatide: Up to 2.24% reduction (SURPASS-3)
Normoglycemia achievement: 69.5% with semaglutide vs 35.8% placebo (SELECT trial)
Diabetes prevention: 94% risk reduction with both semaglutide and tirzepatide

Cardiovascular outcomes

The SELECT trial showed cardiovascular benefits with semaglutide:

20% reduction in major adverse cardiovascular events (MACE)
15% reduction in death from cardiovascular causes
19% reduction in death from any cause
Benefits emerged early: Separation of curves within 3 months

Dosing protocols

Semaglutide titration schedule

Week 1-4: 0.25 mg weekly (initiation dose)
Week 5-8: 0.5 mg weekly
Week 9-12: 1.0 mg weekly
Week 13-16: 1.7 mg weekly (if needed)
Week 17+: 2.4 mg weekly (recommended maintenance for weight loss)
7.2 mg weekly (FDA-approved maximum, after ≥4 weeks tolerating 2.4 mg)

Tirzepatide titration schedule

Week 1-4: 2.5 mg weekly
Week 5-8: 5 mg weekly
Week 9-12: 7.5 mg weekly
Week 13-16: 10 mg weekly
Week 17-20: 12.5 mg weekly
Week 21+: 15 mg weekly (maximum dose)

What to expect week by week

The titration schedules above tell you what to inject. Here is what most patients experience alongside each phase:

Weeks 1-4 (initiation dose)

The first few days after injection one are often the most eventful. Nausea tends to peak during this phase, typically a few hours after injection, then fading within 24-48 hours. Appetite suppression kicks in quickly, sometimes before the nausea resolves. Most patients feel full sooner at meals. Weight loss in this phase is modest, averaging 1-3 lbs, partly from lower calorie intake and partly from reduced water retention.

Weeks 5-12 (dose escalation)

GI side effects generally settle during this period. Each dose step up may trigger a brief recurrence of nausea, but it is usually milder than week one. Weight loss accelerates, with many patients seeing 1-2 lbs per week. Energy levels tend to stabilise as the body adjusts. Appetite changes become most noticeable in this phase: foods that once seemed appealing may trigger less of a response.

Weeks 13-24 (approaching maintenance dose)

By this point, most patients are at or near their maintenance dose. Weight loss rate slows compared to the early weeks but remains consistent. Steady-state drug levels are fully established. This is the phase where lifestyle habits, particularly protein intake, sleep, and resistance training, have the most impact on whether weight loss continues or plateaus. Have your monitoring labs reviewed around week 12.

Important: Each dose escalation should only occur if the current dose is well-tolerated. Some patients achieve excellent results at lower doses and may not need to reach maximum dosing.

Side effects and how to manage them

Common gastrointestinal effects

Incidence rates from clinical trials:

Nausea: 15-30% (usually mild, improves over time)
Diarrhea: 10-15%
Vomiting: 5-10%
Constipation: 5-10%
Abdominal pain: 5-10%

What helps

Dietary modifications:
- Eat smaller, more frequent meals
- Avoid high-fat and spicy foods initially
- Stay hydrated with small, frequent sips
- Stop eating when 80% full
Behavioral strategies:
- Eat slowly and mindfully
- Avoid lying down immediately after meals
- Light physical activity after eating
Medication timing:
- Consider evening injections if morning nausea is problematic
- Maintain consistent injection timing
- Don't skip doses to "avoid" side effects

When to contact your healthcare provider

Seek immediate medical attention for:

Severe abdominal pain (possible pancreatitis)
Persistent vomiting or inability to keep fluids down
Signs of severe hypoglycemia (if on other diabetes medications)
Allergic reactions (rash, difficulty breathing, swelling)
Vision changes (possible diabetic retinopathy progression)
Right upper abdominal pain, particularly after fatty meals (possible gallbladder disease or cholecystitis; GLP-1 therapies are associated with increased gallstone risk)
Decreased urine output or swelling in legs/ankles (possible kidney injury, which can occur from dehydration caused by prolonged vomiting or diarrhea)
New or worsening depression, thoughts of self-harm, or suicidal ideation (the FDA requires monitoring for these symptoms; report them to your prescriber immediately)

Nutrition and exercise on GLP-1 therapy

Protein is the most important variable

GLP-1 medications suppress appetite significantly. The risk is that reduced calorie intake leads to muscle loss alongside fat loss, particularly at higher doses. Protecting muscle mass requires deliberate protein intake.

Daily target: 1.0-1.2g protein per kg of body weight (roughly 0.45-0.55g per lb)
Per-meal target: 25-35g of protein per meal to support muscle protein synthesis
Practical sources: Eggs, Greek yogurt, cottage cheese, chicken, fish, lean red meat, and whey or casein protein supplements
Prioritise protein first: When appetite is reduced, eating protein before carbs and fats ensures you hit your targets even on lower-calorie days

Eating patterns that work well

Smaller, more frequent meals (3-4 per day) rather than large ones; GLP-1 slows gastric emptying and large meals can cause real discomfort
A balanced plate: protein takes up half, vegetables a quarter, complex carbohydrates a quarter
Stay hydrated: aim for at least 2-2.5 litres of water daily; dehydration is common and amplifies fatigue and constipation side effects
Limit alcohol; it contributes empty calories, disrupts sleep quality, and can worsen GI side effects
Stop eating at around 80% fullness; the satiety signal on GLP-1 is stronger than usual, and overeating tends to cause nausea and reflux

Exercise: resistance training takes priority

Cardio has its place, but resistance training is the primary tool for preserving muscle during GLP-1-induced weight loss.

Strength sessions: 2-3 per week, covering major muscle groups (legs, back, chest, shoulders). Compound movements (squats, deadlifts, rows, presses) give the most return per session.
Daily movement: 7,000-10,000 steps per day maintains baseline metabolic rate and cardiovascular health without requiring formal workouts
Start light: If you are new to resistance training, bodyweight exercises and resistance bands are sufficient in weeks 1-8 while your body adapts to the medication
Skip high-intensity on bad days: Intense training during nausea-prone days tends to worsen symptoms. Light walking is better than nothing and rarely makes nausea worse.

What to do when weight loss stalls

Most people hit a plateau at some point. Weight loss with GLP-1 therapy follows a curve: rapid early losses, then a slower phase, then a plateau where the body has adapted. This is normal and does not mean the medication has stopped working.

Common causes of a plateau

Calorie creep: Appetite suppression can diminish as you adapt to a dose, leading to gradual increases in portion size without noticing
Inadequate protein: Muscle loss reduces resting metabolic rate, making further weight loss harder
Insufficient sleep: Poor sleep elevates ghrelin (the hunger hormone) and cortisol, both of which counteract appetite suppression
Reduced activity: The body adapts to lower activity levels over time, burning fewer calories at rest
Dose ceiling: Some patients are at their maximum tolerated dose and have reached the medication's limit at that level

Response tactics

Audit protein intake first; track for 3-5 days. Most people find they have drifted below target without realising it.
Add a strength training session; even one additional session per week can restart metabolic adaptation
Review sleep quality; 7-9 hours is the target; poor sleep is one of the most underestimated plateau drivers
Discuss a dose increase with your prescriber; if you are below your maximum dose and have tolerated the current dose well for 4 or more weeks, this is a reasonable next step
Hold off on switching medications; a plateau at a sub-maximum dose is rarely a sign to change compounds; optimise lifestyle variables first

Clinical trials show that weight loss continues slowly even during apparent plateaus when patients are compliant with both medication and lifestyle changes. Patience at this stage pays off.

Cost, insurance, and how to access treatment

Branded medication: rough price guide

Brand-name GLP-1 medications are expensive without coverage. Rough monthly list prices:

Wegovy (semaglutide for weight loss): approximately $1,350/month without insurance
Ozempic (semaglutide for diabetes): approximately $850-900/month without insurance
Zepbound (tirzepatide for weight loss): approximately $1,060/month without insurance
Mounjaro (tirzepatide for diabetes): approximately $1,000/month without insurance

Manufacturer savings cards can reduce this to $25/month for commercially insured patients who meet eligibility criteria. Novo Nordisk and Eli Lilly both offer these programs; ask your pharmacist or prescriber for details.

Insurance and prior authorisation

Coverage varies widely. The general picture:

Most commercial insurance plans now cover Wegovy and Zepbound with a prior authorisation (PA)
Medicare Part D does not cover weight-loss medications (a rule change is pending as of 2026)
Medicaid coverage varies by state
Prior authorisation typically requires BMI documentation, a letter of medical necessity from your doctor, and sometimes evidence of a previous weight-loss attempt

Compounded alternatives

Compounded semaglutide and tirzepatide are considerably cheaper than branded versions, typically $150-400/month depending on dose and pharmacy. They became widely available during the FDA shortage period and remain accessible through licensed 503B compounding pharmacies.

Compounded versions are not FDA-approved, but the active pharmaceutical ingredient must meet USP standards
Telehealth platforms often bundle the consultation and compounded prescription into a single monthly fee
Quality varies by pharmacy; request a certificate of analysis (CoA) from any compounding pharmacy you use

For more detail, see our guides on compounded semaglutide and compounded tirzepatide.

Using GLP3 Planner to plan your treatment

Your pharmacokinetic profile

GLP3 Planner uses pharmacokinetic modeling to show how medication levels change in your body over time. This is useful for:

Predicting steady-state: Know when your medication will reach stable levels
Understanding dose changes: See how adjustments affect your drug levels
Planning around events: Adjust timing for travel or special occasions
Tracking adherence impact: Visualize effects of missed doses

Step-by-step calculator guide

Step 1: Select Your Medication

Choose from semaglutide, tirzepatide, or retatrutide. Each has different pharmacokinetic properties that affect how long it stays in your system. The calculator automatically applies the correct half-life and absorption parameters.

Step 2: Enter Your Start Date

This helps track your progress and calculate when you'll reach steady-state (typically 4-5 weeks for semaglutide, 2-3 weeks for tirzepatide).

Step 3: Configure Your Dosing Schedule

Add multiple tiers to reflect dose escalation. For each tier, specify:

Duration in weeks
Dose in milligrams
Days of the week (typically once weekly)
Time of day for consistency

Step 4: Generate and Interpret Your Plot

The visualization shows:

Blue line: Drug concentration over time
Red markers: Each dose administration
Steady-state indicator: When levels stabilize
Statistics panel: Peak, trough, and average levels

Advanced features

Weight tracking: Overlay weight changes on your drug level plot
Journal entries: Document side effects, energy levels, and observations
Export capabilities: Download data for healthcare provider discussions
Multiple schedules: Compare different dosing strategies
Biometric integration: Add body weight for accurate volume of distribution calculations

Frequently Asked Questions

How long does it take to see results?

Most patients begin noticing appetite suppression within the first week. Weight loss typically becomes noticeable after 4-8 weeks, with maximum effects seen after reaching steady-state levels and optimal dosing (usually 3-6 months).

Can I switch between different GLP-1 agonists?

Yes, switching is possible and sometimes beneficial. Wait 1-2 weeks after stopping one medication before starting another (allows for washout). Start the new medication at its lowest dose and titrate normally. Consult your healthcare provider for personalized guidance.

What happens if I miss a dose?

If less than 5 days have passed, take the missed dose immediately. If more than 5 days have passed, skip the missed dose and resume your regular schedule. The GLP3 Planner can model the impact of missed doses on your drug levels.

Do I need a prescription to get GLP-1 medications?

Yes. All GLP-1 receptor agonists, including semaglutide and tirzepatide, require a valid prescription from a licensed clinician. You can get one through an in-person visit with your primary care doctor or an obesity medicine specialist, or through a telehealth platform. Telehealth options are often faster and may work directly with compounding pharmacies for lower-cost alternatives.

How much does GLP-1 therapy cost?

Without insurance, branded medications run $850-1,350/month depending on the drug. Manufacturer savings cards can reduce this to $25/month for eligible commercially insured patients. Compounded semaglutide and tirzepatide are typically $150-400/month through licensed 503B compounding pharmacies, and are available via telehealth platforms without the prior authorisation process.

How do I inject GLP-1 medications?

GLP-1 medications are injected subcutaneously (under the skin) once weekly. Common sites are the abdomen (at least 2 inches from the navel), the front of the thigh, or the upper outer arm. Rotate sites each week. Branded pens are pre-filled and single-use; press the cap against the skin, click to inject, and hold for 5-10 seconds. Compounded versions use an insulin syringe and require drawing up the dose from a vial. See our reconstitution guides for step-by-step instructions.

What do I do if I hit a weight loss plateau?

Plateaus are normal. Start by auditing your protein intake for a few days; most people find they have drifted below their target. Add a strength training session per week if you are not already doing resistance training. Review sleep quality (7-9 hours is the target). If you are below your maximum tolerated dose, discuss a dose increase with your prescriber. Avoid switching medications before optimising these lifestyle variables.

Can I drink alcohol on GLP-1 medications?

Alcohol is not contraindicated, but there are good reasons to limit it. GLP-1 medications already reduce appetite and slow gastric emptying; alcohol on top of this can worsen nausea and increase the risk of low blood sugar if you are also on a diabetes medication like sulfonylurea or insulin. Many patients also report that their tolerance for alcohol drops significantly on GLP-1 therapy, with smaller amounts producing stronger effects. Moderate intake (1-2 drinks occasionally) is generally fine, but heavy drinking works against both the weight loss and the medication.

How is tirzepatide different from semaglutide?

Semaglutide is a GLP-1 receptor agonist only. Tirzepatide is a dual GIP/GLP-1 receptor agonist, activating both the GIP and GLP-1 pathways simultaneously. This dual mechanism produces additive effects on insulin secretion and appears to drive greater weight loss on average. The SURMOUNT-1 trial showed 20.9% weight loss with tirzepatide 15mg at 72 weeks, compared to 14.9% with semaglutide 2.4mg (STEP 1, 68 weeks). Side effect profiles are similar, though tirzepatide's titration schedule is more gradual. Cost is roughly comparable for branded versions.

Are these medications safe for long-term use?

Current evidence supports long-term safety. The SELECT trial followed patients for 4+ years with semaglutide, showing continued benefits and no new safety signals. However, these are relatively new medications, and post-market surveillance continues.

What's coming next

In development

Oral formulations: Daily oral semaglutide already approved, more in development
Monthly injections: Extended-release formulations in clinical trials
Combination therapies: GLP-1 agonists plus other mechanisms
Expanded indications: Sleep apnea, NASH/MASH, heart failure, osteoarthritis
Next-generation agonists: Quadruple agonists and small molecule alternatives

Personalized treatment

GLP-1 therapy is moving toward more individualized approaches:

Genetic testing to predict response and side effects
Biomarker-guided dose optimization
AI-driven personalization of treatment protocols
Integration with continuous glucose monitoring and wearables

Important Medical Disclaimer

GLP3 Planner is an educational tool designed to help visualize pharmacokinetics and track medication schedules. It should not replace professional medical advice, diagnosis, or treatment. The information provided is based on clinical trial data and may not reflect individual variations in response.

Always consult with your healthcare provider before starting, stopping, or changing any medication regimen. Individual responses can vary significantly based on genetics, concurrent medications, kidney function, and other medical conditions. Your healthcare provider can help determine the most appropriate treatment plan for your specific situation.